Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 6/20 | 0.75 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.68 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.67 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.67 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.67 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.61 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30047050 | 1.00 | RNASEL (0.75) | RNASELP2RY1ENPP1P2RY12P2RY11 | |
| SCHEMBL2020893 | 0.99 | RNASEL (0.77) | RNASELP2RY1ENPP1P2RY12P2RY11 | |
| SCHEMBL29494944 | 0.93 | RNASEL (0.72) | RNASELP2RY1ENPP1P2RY12P2RY11 | |
| SCHEMBL2463663 | 0.93 | RNASEL (0.72) | RNASELP2RY1ENPP1P2RY12P2RY11 | |
| SCHEMBL30055318 | 0.92 | RNASEL (0.87) | RNASELP2RY1ENPP1P2RY12P2RY11 | |
| SCHEMBL29423355 | 0.91 | RNASEL (0.89) | RNASELP2RY1ENPP1P2RY12P2RY11 | |
| SCHEMBL29814022 | 0.89 | RNASEL (0.67) | RNASELP2RY1ENPP1P2RY12P2RY11 | |
| SCHEMBL16700308 | 0.89 | RNASEL (0.67) | RNASELP2RY1ENPP1P2RY12P2RY11 | |
| SCHEMBL30969952 | 0.88 | RNASEL (0.61) | RNASELP2RY1P2RY12 | |
| SCHEMBL20266295 | 0.88 | RNASEL (0.61) | RNASELP2RY1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9759730-B2 | Method and device for the determination of platelet function under flow conditions | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2017-09-12 | — | — | US | claimed |
| US-20150093770-A1 | METHOD AND DEVICE FOR THE DETERMINATION OF PLATELET FUNCTION UNDER FLOW CONDITIONS | SIEMENS HEALTHCARE DIAGNOSTICS (DE) | 2015-04-02 | — | — | US | claimed |
| US-8895259-B2 | Method for determination of platelet function under flow conditions | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2014-11-25 | — | — | US | claimed |
| US-8618074-B2 | GPCR enhanced neuroprotection to treat brain injury | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-12-31 | — | — | US | claimed |
| EP-1850134-B1 | Method and Apparatus for the determination of the Thromboyte function and flow conditions | SIEMENS HEALTHCARE DIAGNOSTICS (DE) | 2013-01-30 | — | — | EP | claimed |
| US-7960131-B2 | Functional genomic pore assay for mixed cell populations | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-06-14 | — | — | US | claimed |
| EP-1850135-B1 | Method for determining the thrombocyte function and flow conditions | SIEMENS HEALTHCARE DIAGNOSTICS (DE) | 2010-11-03 | — | — | EP | claimed |
| US-20100216735-A1 | GPCR ENHANCED NEUROPROTECTION TO TREAT BRAIN INJURY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-08-26 | — | — | US | claimed |
| US-7560243-B2 | White blood cell functional assay | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-07-14 | — | — | US | claimed |
| US-20090053204-A1 | Functional Genomic Pore Assay For Mixed Cell Populations | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-02-26 | — | — | US | claimed |
| US-20070254324-A1 | Method for determination of platelet function under flow conditions | DADE BEHRING MARBURG GMBH | 2007-11-01 | — | — | US | claimed |
| US-20070254325-A1 | Method and device for the determination of platelet function under flow conditions | DADE BEHRING MARBURG GMBH | 2007-11-01 | — | — | US | claimed |
| US-20050053612-A1 | Nucleotide regulation of immune responses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| US-20040253650-A1 | White blood cell functional assay | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-12-16 | — | — | US | claimed |
| US-20030059878-A1 | Novel purinoceptor and gene thereof | TANABE SEIYAKU CO., LTD (JP) | 2003-03-27 | — | — | US | claimed |
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-117241803-A | Purine nucleosides, intermediates and methods of making the same | 阿斯特罗赛特制药公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2001051490-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-1047699-A1 | PLATELET ADP RECEPTOR INHIBITORS | COR THERAPEUTICS, INC. (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036425-A1 | PLATELET ADP RECEPTOR INHIBITORS | COR THERAPEUTICS, INC. (US) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216735-A1 | GPCR ENHANCED NEUROPROTECTION TO TREAT BRAIN INJURY | P2RY1, P2RY2, P2RY11 | RNASEL 3067/4885P2RY1 1/4885ENPP1 345/4885 |
| US-20050053612-A1 | Nucleotide regulation of immune responses | NT5C2, ENTPD5, ENTPD1 | RNASEL 664/4885P2RY1 7/4885ENPP1 44/4885 |
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | NUDT1, PNP, UMPS | RNASEL 229/4885P2RY1 77/4885ENPP1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.